All News
RheumNow Podcast - COVID Kids and Men (5.15.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
RheumNow Podcast – The Beat Goes On (5.8.20)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
German Society of Rheumatology COVID Pandemic Recommendations
The Annals of Rheumatic Disease has published the preliminary recommendations of the German Society of Rheumatology for the management of Inflammatory rheumatic diseases patients during the SARS-CoV-2/Covid-19 pandemic.
These preliminary recommendations are based on an expert consensus from 17 experienced German rheumatologists.
RheumNow Podcast – In Times of Trouble (4.24.20)
Dr Jack Cush reviews the news, journal reports, twitter feed and COVID developments from the past week on RheumNow.com
Read Article
COVID-19 Systemic Involvement
The presentations of the COVID-19 infection have been clearly chronicled with the worrisome onset of sore throat, dry cough, loss of smell and taste with fevers, myalgias, fatigue and the worrisome progression of pulmonary involvement in a minority. Lab findings may include a leukocytosis,
Read Article
RheumNow Podcast – The Beginning of Something Else (4.10.20)
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com
Read Article
TNR - Grand Rounds: Safety of Biologics & New Agents
On Tuesday, April 7th, RheumNow hosted its first Tuesday Nite Rheumatology webinar - kicking off a two-month series of Rheumatology Grand Rounds lectures. The first session featured Jack Cush, MD (UT Southwestern) who lectured on "The Safety of Biologics and Newer Agents".
Read Article
EMA Final Recommendations on VTE Risk with Tofacitinib
On 14 November 2019 the European Medicines Agency (EMA) concluded that Xeljanz (tofacitinib) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk. These recommendations have been formally published and are intended for EU nation
Read Article
Adverse Effects of Low-Dose Methotrexate from the CIRT Trial
Low-dose methotrexate (LD-MTX) was studied in high risk cardiac patients in the cardiac intervention trial (CIRT), but was prematurely ended for not showing a change in cardiovascular event rates. Nonetheless this trial studied the safety and adverse event rates of LD-MTX and those results are reported in the current issue of Annals of Internal Medicine.
Biosimilars for Rheum Disease: Failure to Launch
The availability of biologic biosimilars has thus far had negligible impact on prescribing practices in the United States, in stark contrast to what has been observed in some European countries, researchers reported.
Read Article
NSAID Safety Guidelines
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for acute or chronic arthritis, headache, visceral pain, postoperative pain, etc but come with a small but significant risk of serious adverse effects, including hypertension, cardiovascular disease, kidney injury and GI complica
Read Article
Best of 2019 - Biologic Safety Guidelines from the British Society for Rheumatology
In the United Kingdom, NICE has looked to the British Society of Rheumatology (BSR) to develop evidence based guidance on the safe use of biologic DMARDs in patients with inflammatory arthritis.
Read Article
RheumNow Podcast - The Elusive Hand OA Problem (12.13.19)
Dr. Jack Cush recaps the news and journal reports from the past week on RheumNow.com.
Read Article
Biologic Safety Guidelines from the British Society for Rheumatology
In the United Kingdom, NICE has looked to the British Society of Rheumatology (BSR) to develop evidence based guidance on the safe use of biologic DMARDs in patients with inflammatory arthritis.
Read Article
Apremilast Reduces Oral Ulcers in Behcet's Syndrome
A multinational trial finds a statistically significant number of patients with Behçet's syndrome showed a greater reduction in the number of oral ulcers with apremilast compared with placebo.
Read Article
Voluntary Recall of Zantac by Sanofi/FDA
Sanofi has initiated a voluntary recall of all Zantac OTC (over-the-counter) products in the United States. This includes Zantac 150®, Zantac 150® Cool Mint, and Zantac 75®.
Read Article
FDA Approves Ustekinumab for Ulcerative Colitis
Ustekinumab (Stelara) is now FDA-approved to treat moderately to severely active ulcerative colitis, said drugmaker Janssen on Monday, in addition to its indications for psoriasis, psoriatic arthritis, and Crohn's disease.
Read Article
Comorbidity Worsens Axial Spondyloarthritis
Comorbidities are common in patients with axial spondyloarthropathy (axSpA), and a recent study has shown that multimorbidity, the coexistence of 2 or more conditions, is associated with more severe disease than those without comorbidities.
Read Article
Ustekinumab Efficacy in Ulcerative Colitis
The NEJM reports the results of a one year trial wherein ustekinumab (UST) was shown to be effective at inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. Ustekinumab, currently approved for use in psoriasis, psoriatic arthritis and Crohn's disease, is a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23.
Read Article
Persistent Inflammatory Arthritis After Immune Checkpoint Inhibitors
Braaten and colleagues from Johns Hopkins School of Medicine have reported their experience with chronic inflammatory arthritis induced by immune checkpoint inhibitor therapies, showing that in some, inflammatory arthritis persists after the immunotherapy has been discontinued.